Arcturus Therapeutics 주식 (NASDAQ: ARCT)

에 대한 최신 뉴스 Arcturus Therapeutics (NASDAQ:ARCT) 주식

Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases. It operates in the research and development segment of medical applications for nucleic acid-focused technology. The company's product pipeline includes LUNAR-OTC, LUNAR-CF, LUNAR-FLU and LUNAR-COV19.

Equities

News

Markets

ETFs

ARCT

ARKK

ARKQ

ARKW

BLDE

MKFG

NVDA

ROKU

2024년 6월 25일 화요일, 캐시 우드가 주도하는 아크 인베스트(Ark Invest)는 상당한 시장 변동성 속에서 엔비디아(NASDAQ:NVDA)와 로쿠(NASDAQ:ROKU)에서 상당한 거래를 했다. 이러한 거래는 아크의 다양한 ETF가 이행한 일련의 거래의 일부였다.

아크 인베스트는 주가 반등 속에 엔비디아 주식에서 $430만 매도, 로쿠 주식을 매수

$BTC

$ETH

ARKF

ARKG

ARKX

HOOD

TDOC

VERV

캐시 우드가 이끄는 아크 인베스트(Ark Invest)는 수요일에 로빈후드 마켓(NASDAQ:HOOD) 및 줌 비디오 커뮤니케이션(NASDAQ:ZM)괴 관련하여 상당한 거래를 했다.
로빈후드 주식의 거래

아크 인베스트는 로빈후드 주식 150만 달러를 매도하며, 줌 주식 330만 달러 상당도 처분

EXAS

NTLA

VCYT

월요일에 캐시 우드가 주도하는 아크 인베스트(Ark Invest)는 로빈후드 마켓(NASDAQ:HOOD)의 지분을 줄이는 중요한 조치를 취했다. 이 결정은 시장 변동 기간 중에 이루어졌으며 이 투자 회사가 자체 포트폴리오를 조정하는 최근 추세를 따랐다.
로빈후드(HOOD) 매매:

아크 인베스트가 게임스톱 관련 뉴스와 비트코인 변동성 속에서 로빈후드 주식 $7.6백만 매각

Arcturus Therapeutics Holdings Inc. - Common Stock

Arcturus Therapeutics Holdings Inc

ARCTIC STAR EXPL CORP by Arctic Star Exploration Corp.

Arctic Star Exploration Corp

HC Wainwright &amp; Co. analyst Ed Arce reiterates Arcturus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARCT#NASDAQ">ARCT</a>) with a Buy and maintains $63 price target.

Price Target

Reiteration

Analyst Ratings

HC Wainwright & Co. Reiterates Buy on Arcturus Therapeutics, Maintains $63 Price Target

Biotech

General

Arcturus Therapeutics Initiates Phase 1 H5N1 Flu Vaccine Trial

HC Wainwright &amp; Co. analyst Ed Arce maintains Arcturus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARCT#NASDAQ">ARCT</a>) with a Buy and maintains $63 price target.

HC Wainwright & Co. Maintains Buy on Arcturus Therapeutics, Maintains $63 Price Target

First participants initiated Phase 2 dosing for both CF and OTC deficiency in December 2024
Phase 2 interim data for both mRNA therapeutic programs on track for first half of 2025
Arcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:<a href="https://www.benzinga.com/stock/ARCT#NASDAQ">ARCT</a>), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced that the first CF and OTC deficiency participants initiated dosing in December 2024, in the Company's Phase 2 multiple ascending dose studies.
Each participant in the Phase 2 CF study (<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT06747858%3Fcond%3DCystic%2520Fibrosis%26term%3Darcturus%26rank%3D2&amp;esheet=54173841&amp;newsitemid=20250106386740&amp;lan=en-US&amp;anchor=NCT06747858&amp;index=1&amp;md5=bb147966a36afe3940f2894d41fe36ab">NCT06747858</a>) is expected to receive daily treatments of ARCT-032 over a period of 28 days.
The first OTC deficient participant receiving 0.5 mg/kg ARCT-810 initiated dosing in December 2024 in the United States. Each participant is expected to receive five intravenous infusions administered over two months. The Company previously announced the completion of the dosing phase (N = 8; 0.3 mg/kg) in a placebo-controlled European study enrolling OTC deficient individuals and expansion of the Phase 2 clinical program of ARCT-810 into the United States with an open-label multiple-dose study (<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT06488313&amp;esheet=54173841&amp;newsitemid=20250106386740&amp;lan=en-US&amp;anchor=NCT06488313&amp;index=2&amp;md5=34a550d7cb146fc9a95177ef24585dd6">NCT06488313</a>).

Arcturus Therapeutics Announces Initiation Of Dosing In Phase 2 Multiple Ascending Dose Studies For Cystic Fibrosis And Ornithine Transcarbamylase Deficiency; Phase 2 Interim Data For Both mRNA Therapeutic Programs On Track For First Half Of 2025

Cantor Fitzgerald analyst Pete Stavropoulos reiterates Arcturus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARCT#NASDAQ">ARCT</a>) from Overweight to Overweight.

Cantor Fitzgerald Reiterates Overweight on Arcturus Therapeuticsto Overweight

Meiji Seika Pharma Invests In ARCALIS, Expects To Enhance Japan's mRNA Vaccine Infrastructure

Arcturus Therapeutics Receives FDA Clearance To Begin H5N1 Pandemic Flu Vaccine Clinical Trial

Arcturus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARCT#NASDAQ">ARCT</a>) reported quarterly losses of $(0.26) per share which beat the analyst consensus estimate of $(1.19) by 78.15 percent. The company reported quarterly sales of $41.673 million which beat the analyst consensus estimate of $36.597 million by 13.87 percent. This is a 7.68 percent decrease over sales of $45.140 million the same period last year.

Earnings

Earnings Beats

Arcturus Therapeutics Q3 2024 GAAP EPS $(0.26) Beats $(1.19) Estimate, Sales $41.673M Beat $36.597M Estimate

Providing a diverse range of perspectives from bullish to bearish, 3 analysts have published ratings on Arcturus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARCT#NASDAQ">ARCT</a>) in the last three months.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Arcturus Therapeutics, revealing an average target of $65.33, a high estimate of $70.00, and a low estimate of $63.00. This current average reflects an increase of 6.23% from the previous average price target of $61.50. 
<img src="https://www.benzinga.com/files/images/story/2024/1727816432_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
A comprehensive examination of how financial experts perceive Arcturus Therapeutics is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ed Arce</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$63.00</td>
<td>$63.00</td>
</tr>
<tr>
<td>Lili Nsongo</td>
<td>Leerink Partners</td>
<td>Announces</td>
<td>Outperform</td>
<td>$70.00</td>
<td>-</td>
</tr>
<tr>
<td>Ed Arce</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$63.00</td>
<td>$60.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Arcturus Therapeutics. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Arcturus Therapeutics compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Arcturus Therapeutics's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Arcturus Therapeutics's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/ARCT/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Arcturus Therapeutics analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Delving into Arcturus Therapeutics's Background</h2>
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases. It operates in the research and development segment of medical applications for nucleic acid-focused technology. The company's product pipeline includes LUNAR-OTC, LUNAR-CF, LUNAR-FLU and LUNAR-COV19.
<h3>Understanding the Numbers: Arcturus Therapeutics's Finances</h3>
Market Capitalization Analysis: The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.
Revenue Growth: Arcturus Therapeutics displayed positive results in 3 months. As of 30 June, 2024, the company achieved a solid revenue growth rate of approximately 380.67%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of -37.45%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Arcturus Therapeutics's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -6.59%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Arcturus Therapeutics's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -4.26%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: Arcturus Therapeutics's debt-to-equity ratio is below the industry average. With a ratio of 0.12, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Unveiling 3 Analyst Insights On Arcturus Therapeutics

CSL Limited (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CSLLY#OTC">CSLLY</a>)&nbsp;and Arcturus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARCT#NASDAQ">ARCT</a>)&nbsp;announced the results of a Phase 3 head-to-head study of ARCT-154, a self-amplifying (sa-mRNA) COVID-19 vaccine, compared to Pfizer Inc&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) <a target="_blank" href="https://www.benzinga.com/pressreleases/24/09/b41089773/self-amplifying-mrna-covid-19-vaccine-demonstrates-superior-immune-response-compared-with-mrna-vac" rel="noreferrer noopener">shot Comirnaty</a>.
The study showed that the sa-mRNA COVID-19 vaccine maintained superior immunogenicity compared to the conventional mRNA vaccine Comirnaty&nbsp;for up to one year against Wuhan-Hu-1, Omicron&nbsp;BA.4-5&nbsp;and certain other variants, and at one-sixth the dose of the comparator&nbsp;(5 μg vs. 30 μg, respectively).
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/06/39234193/arcturus-inhaled-mrna-therapeutic-in-cystic-fibrosis-study-highlights-potential-ami" rel="noreferrer noopener">Arcturus&#8217; Inhaled mRNA Therapeutic In Cystic Fibrosis Study Highlights Potential Amid Competitive Landscape: Analyst</a>.
The COVID-19 vaccine from this sa-mRNA platform targeted against the JN.1 variant is approved in Japan for immunization against COVID-19 in adults 18 years and older. It is being sold under the trade name Kostaive.
At Day 29, neutralizing antibodies (GMTs unadjusted) against the Wuhan-Hu-1 strain in ARCT-154 recipients (n = 378) were superior to those in the Comirnaty&nbsp;group (n = 374)
<ul>
<li>GMT = 5390 vs. 3738, a GMT ratio of 1.44. This advantage persisted through all time points.</li>
<li>At Day 361 (unadjusted), GMTs were 3396 and 1771 in ARCT-154 (n = 272) and Comirnaty (n = 266) groups, with a GMT ratio of 1.92.</li>
<li>Differences were also observed in responses against Omicron BA.4-5, with GMT ratios of 1.31 at Day 29 and 1.89 at Day 361.</li>
</ul>
Additional data presented by CSL and Arcturus finds that the bivalent formula ARCT-2301, developed on the same platform as ARCT-154, induces superior immunogenicity over conventional bivalent mRNA vaccine Comirnaty, which persists against key variants up to six months postvaccination.
<ul>
<li>Data from 930 participants showed that ARCT-2301 (n = 398) induced superior neutralizing antibody responses vs. Comirnaty (n = 405) against Omicron BA.4-5 (GMT ratio 1·49), and against Wuhan-Hu-1 (GMT ratio 1.45).</li>
<li>The difference persisted through six months with GMT ratios of 2.17 and 1.98, respectively.</li>
<li>Antibody responses against Omicron XBB.1.5 were also higher after ARCT-2301 vs. Comirnaty.</li>
</ul>
Price Action: ARCT stock is up 4.70% at $23.07 at last check Monday.
Image via Unsplash
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/09/41091774/prime-medicine-inks-cell-therapy-pact-with-bristol-myers-squibb-worth-over-3-5b-streamlines-pipel" target="_blank" rel="noreferrer noopener">Prime Medicine Inks Cell Therapy Pact With Bristol Myers Squibb Worth Over $3.5B, Streamlines Pipeline</a>.</li>
</ul>

Large Cap

Health Care

CSLLY

Arcturus Therapeutics/CSL Partnered COVID-19 Vaccine Surpasses Pfizer's Comirnaty Shot, Even At Lower Doses

Arcturus Therapeutics And CSL Announce Results Of Head-To-Head Study Showing Self-Amplifying mRNA COVID-19 Vaccine Demonstrated Superior Immune Response Compared With mRNA Vaccine At 12 Months Post-Vaccination

Arcturus Therapeutics'Announces Japan's Ministry of Health, Labor and Welfare Approved The Company and CSL's Updated mRNA COVID-19 Vaccine For Protection Against JN.1 Strain

Cantor Fitzgerald analyst Josh Schimmer reiterates Arcturus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARCT#NASDAQ">ARCT</a>) with a Overweight.

Cantor Fitzgerald Reiterates Overweight on Arcturus Therapeutics

Arcturus Therapeutics (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/arct#NASDAQ">ARCT</a>) closed the last trading session at $21.10, gaining 2.7% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $66.75 indicates a 216.4% upside potential.
The average comprises eight short-term price targets ranging from a low of $18 to a high of $140, with a standard deviation of $35.48. While the lowest estimate indicates a decline of 14.7% from the current price level, the most optimistic estimate points to a 563.5% upside. More than the range, one should note the standard deviation here, as it helps understand the variability of the estimates. The smaller the standard deviation, the greater the agreement among analysts.
While the consensus price target is a much-coveted metric for investors, solely banking on this metric to make an investment decision may not be wise at all. That&#39;s because the ability and unbiasedness of analysts in setting price targets have long been questionable.
However, an impressive consensus price target is not the only factor that indicates a potential upside in ARCT. This view is strengthened by the agreement among analysts that the company will report better earnings than what they estimated earlier. Though a positive trend in earnings estimate revisions doesn&#39;t give any idea as to how much the stock could surge, it has proven effective in predicting an upside.
<h2>Here&#39;s What You Should Know About Analysts&#39; Price Targets</h2>
According to researchers at several universities across the globe, a price target is one of many pieces of information about a stock that misleads investors far more often than it guides. In fact, empirical research shows that price targets set by several analysts, irrespective of the extent of agreement, rarely indicate where the price of a stock could actually be heading.
While Wall Street analysts have deep knowledge of a company&#39;s fundamentals and the sensitivity of its business to economic and industry issues, many of them tend to set overly optimistic price targets. Are you wondering why?
They usually do that to drum up interest in shares of companies that their firms either have existing business relationships with or are looking to be associated with. In other words, business incentives of firms covering a stock often result in inflated price targets set by analysts.
However, a tight clustering of price targets, which is represented by a low standard deviation, indicates that analysts have a high degree of agreement about the direction and magnitude of a stock&#39;s price movement. While that doesn&#39;t necessarily mean the stock will hit the average price target, it could be a good starting point for further research aimed at identifying the potential fundamental driving forces.
That said, while investors should not entirely ignore price targets, making an investment decision solely based on them could lead to disappointing ROI. So, price targets should always be treated with a high degree of skepticism.
<h2>Here&#39;s Why There Could be Plenty of Upside Left in ARCT</h2>
There has been increasing optimism among analysts lately about the company&#39;s earnings prospects, as indicated by strong agreement among them in revising EPS estimates higher. And that could be a legitimate reason to expect an upside in the stock. After all, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For the current year, four estimates have moved higher over the last 30 days compared to no negative revision. As a result, the Zacks Consensus Estimate has increased 45.1%.
Moreover, ARCT currently has a Zacks Rank #1 (Strong Buy), which means it is in the top 5% of more than the 4,000 stocks that we rank based on four factors related to earnings estimates. Given an impressive externally-audited track record, this is a more conclusive indication of the stock&#39;s potential upside in the near term.
Therefore, while the consensus price target may not be a reliable indicator of how much ARCT could gain, the direction of price movement it implies does appear to be a good guide.
<a href="https://www.zacks.com/stock/news/2330343/does-arcturus-therapeutics-arct-have-the-potential-to-rally-216-35-as-wall-street-analysts-expect?cid=CS-BENZ-FT-tale_of_the_tape|consensus_price_target-2330343">To read this article on Zacks.com click here.</a>

Small Cap

Trading Ideas

Does Arcturus Therapeutics Have the Potential to Rally 216.35% as Wall Street Analysts Expect?

Arcturus Therapeutics Receives Clearance Of Investigational New Drug Application For ARCT-032 To Treat Cystic Fibrosis

AN2 Therapeutics&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/antx#NASDAQ">ANTX</a>), a clinical-stage company, leverages its boron chemistry platform to develop novel small molecule therapeutics to potentially treat various infectious diseases and cancer indications.
The company is currently evaluating its lead clinical-stage candidate, epetraborole, a bacterial leucyl-tRNA synthetase inhibitor, for nontuberculous mycobacteria (NTM) lung disease and acute melioidosis in separate early-stage studies.
In the past month, shares of AN2 Therapeutics plunged 66.3% after the company announced that it has discontinued its mid to late-stage study on epetraborole for patients with treatment-refractory mycobacterium avium complex lung disease due to unsatisfactory efficacy results.
Year to date, shares of ANTX have plummeted 95.2% compared with the industry&#39;s 1.7% decline.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/50/74594.jpg?v=2118867417" style="height:310px; width:600px" />
Image Source: Zacks Investment Research
On Aug 8, AN2 Therapeutics announced top-line results from the phase II portion of the phase II/III EBO-301 study evaluating epetraborole in combination with an optimized background regimen (OBR) in treatment-refractory MAC lung disease.&nbsp;
Per ANTX, the EBO-301 study met its primary endpoint, potentially validating a novel patient-reported outcome&nbsp;tool and a higher PRO-based clinical response rate of 39.5% in the epetraborole arm compared with the 25% observed in the placebo arm, when combined with OBR.
However, the MAC lung disease study failed to demonstrate a statistically significant, superior sputum culture conversion at month six, a key secondary endpoint, in the epetraborole + OBR arm compared with the placebo + OBR arm. On the contrary, the sputum culture conversion at month six was similar between the treatment arms.
We remind the investors that in February 2024, AN2 Therapeutics had voluntarily suspended new patient enrollment in the phase III portion of the EBO-301 study due to potentially lower-than-expected efficacy observed in blinded aggregate data.
Following the latest data from the phase II/III study announced in August, the company terminated the phase II as well as the phase III portion of the EBO-301 study.
AN2 Therapeutics clarified that the candidate was generally well-tolerated, and the study was not terminated due to safety concerns.
Following the massive setback, the company will further evaluate the EBO-301 study results to determine the next steps for the potential future development of epetraborole to treat NTM lung disease in other patient populations.
The company also plans to invest heavily in research and developmental activities to accelerate the development of several pre-clinical candidates for infectious diseases and oncology. Simultaneously, AN2 Therapeutics plans to undergo strategic restructuring with the intent of extending its cash runway through 2027.
In an SEC filing, the company stated that it will slash its workforce by approximately 50% by the end of 2024, as part of its strategic restructuring efforts. ANTX anticipates the charges for such a reduction in workforce in the range of $2-$3 million, including severance and other employee-termination related expenses.
Currently, AN2 Therapeutics is gearing up to initiate a phase I clinical study of its second product candidate, AN2-502998, to cure chronic Chagas disease. The company is also planning to initiate a mid-stage study of epetraborole for the melioidosis indication.
<div class="chart_embed">
<h3>AN2 Therapeutics, Inc. Price and Consensus</h3>
<img alt="AN2 Therapeutics, Inc. Price and Consensus" src="https://staticx-tuner.zacks.com/images/charts/94/1724071843.png" style="height:310px; width:600px" title="" />
AN2 Therapeutics, Inc. price-consensus-chart | AN2 Therapeutics, Inc. Quote
</div>
<h3>Zacks Rank &amp; Other Stocks to Consider</h3>
AN2 Therapeutics currently carries a Zacks Rank #2 (Buy).&nbsp;
Some other top-ranked stocks in the overall healthcare sector include&nbsp;Illumina, Inc.&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ilmn#NASDAQ">ILMN</a>),&nbsp;Fulcrum Therapeutics&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/fulc#NASDAQ">FULC</a>) and&nbsp;Arcturus Therapeutics&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/arct#NASDAQ">ARCT</a>), each sporting a Zacks Rank #1 (Strong Buy) at present.
In the past 60 days, estimates for Illumina&#39;s 2024 earnings per share have moved up from $1.07 to $3.16. Earnings per share estimates for 2025 have improved from $2.93 to $4.49. Year to date, shares of ILMN have lost 6.4%.
Illumina&#39;s earnings beat estimates in each of the trailing four quarters, the average surprise being 463.46%.
In the past 60 days, the consensus estimate for Fulcrum Therapeutics&#39; 2024 loss per share has narrowed from $1.24 to 48 cents. The consensus estimate for 2025 loss per share has narrowed from $1.71 to $1.51 during the same period. Year to date, shares of FULC have jumped 36.9%.
Fulcrum Therapeutics beat earnings estimates in each of the last four quarters, delivering an average earnings surprise of 393.18%.
In the past 60 days, estimates for Arcturus Therapeutics&#39; 2024 loss per share have improved from $4.39 to $2.60. The estimate for 2025 is currently pegged at earnings of 21 cents per share. Year to date, shares of Arcturus Therapeutics have lost 35.9%.
Earnings of Arcturus Therapeutics beat estimates in each of the last four quarters, delivering a four-quarter average earnings surprise of 56.73%.
<a href="https://www.zacks.com/stock/news/2323887/an2-therapeutics-antx-plunges-66-in-a-month-here-s-why?cid=CS-BENZ-FT-analyst_blog|price_surge_/_plunge-2323887">To read this article on Zacks.com click here.</a>

Penny Stocks

ANTX

FULC

ILMN

AN2 Therapeutics Plunges 66% in a Month: Here's Why

Leerink Partners analyst Lili Nsongo initiates coverage on Arcturus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARCT#NASDAQ">ARCT</a>) with a Outperform rating and announces Price Target of $70.

Initiation

Leerink Partners Initiates Coverage On Arcturus Therapeutics with Outperform Rating, Announces Price Target of $70

Arcturus gets FDA clearance for H5N1 avian flu vaccine study

Arcturus: LUNAR-CF For CF Presses On With 1st Half Of 2025 Interim Data

Leerink Partners analyst Lili (Aurélie) Nsongo has maintained their bullish stance on ARCT stock, giving a Buy rating on November 8. Lili (Aurélie)...

Buy Rating for ARCT Driven by Strategic Insights and Promising Vaccine Prospects

In a report released today, Whitney Ijem from Canaccord Genuity maintained a Buy rating on Arcturus Therapeutics (ARCT – Research Report), with a p...

Positive Outlook for Arcturus Therapeutics Driven by Innovative Vaccine Kostaive

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Arcturus Therapeutics (ARCT – Research Report) and M...

Analysts Offer Insights on Healthcare Companies: Arcturus Therapeutics (ARCT) and Madrigal Pharmaceuticals (MDGL)

Arcturus Therapeutics (ARCT) Holdings announced that the first CF and OTC deficiency participants initiated dosing in December 2024, in the company...

Arcturus initiates dosing in Phase 2 studies for CF and OTC deficiency

Moderna, Novavax and other vaccine names extend gains amid COVID/flu concerns

Arcturus up 9% as phase 2 dosing begins for mRNA asset for cystic fibrosis

In a report released yesterday, Yasmeen Rahimi from Piper Sandler initiated coverage with a Buy rating on Arcturus Therapeutics (ARCT – Research Re...

Arcturus Therapeutics (ARCT) Initiated with a Buy at Piper Sandler

In a report released today, Ed Arce from H.C. Wainwright maintained a Buy rating on Arcturus Therapeutics (ARCT – Research Report), with a price ta...

Buy Rating for Arcturus Therapeutics Driven by Promising Vaccine Candidate and Strategic Partnerships

BNTX

CVAC

MDGL

MRNA

NVAX

Press Releases

Self-Amplifying mRNA COVID-19 Vaccine Demonstrates Superior Immune Response Compared with mRNA Vaccine at 12 Months Post-Vaccination

Arcturus Therapeutics to Report Third Quarter Financial Results and Provide Corporate Update on November 7, 2024

Arcturus Therapeutics Announces Third Quarter 2024 Financial Update and Pipeline Progress

Arcturus Therapeutics Receives Clearance from FDA to Begin H5N1 Pandemic Flu Vaccine Clinical Trial

Meiji Seika Pharma Announces Investment in ARCALIS, Inc.

Arcturus Therapeutics to Present at Jefferies London Healthcare Conference

Arcturus Therapeutics to Attend Upcoming Investor Conferences

Arcturus Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Arcturus Therapeutics Announces Initiation of Dosing in Phase 2 Multiple Ascending Dose Studies for Cystic Fibrosis (CF) and Ornithine Transcarbamylase (OTC) Deficiency

Arcturus Therapeutics Announces Initiation of Phase 1 H5N1 Flu Vaccine Trial

Abivax

Akebia Therapeutics

Allogene Therapeutics, Inc. - Common Stock

Allogene Therapeutics

Altimmune

AnaptysBio

Annexon

Astria Therapeutics

Celcuity

Cargo Therapeutics

Emergent BioSolutions

Kodiak Sciences

Keros Therapeutics

MeiraGTx Hldgs

Mineralys Therapeutics, Inc. - Common Stock

Mineralys Therapeutics

Mereo BioPharma Group plc - American Depositary Shares

Mereo BioPharma Group

Opthea Limited - American Depositary Shares

Opthea

Oruka Therapeutics

PureTech Health plc - American Depositary Shares

PureTech Health

Cartesian Therapeutics, Inc. - Common Stock

Cartesian Therapeutics

Sage Therapeutics

Stoke Therapeutics

Savara

Entrada Therapeutics, Inc. - Common Stock

Entrada Therapeutics

Tourmaline Bio

Verve Therapeutics

HC Wainwright & Co.

Leerink Partners

Canaccord Genuity

Wells Fargo

2024년 6월 25일 화요일, 캐시 우드가 주도하는 아크 인베스트(Ark Invest)는 상당한 시장 변동성 속에서 엔비디아(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>)와 로쿠(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROKU#NASDAQ">ROKU</a>)에서 상당한 거래를 했다. 이러한 거래는 아크의 다양한 ETF가 이행한 일련의 거래의 일부였다.
엔비디아 거래
이 회사의 ARK 자율 기술 및 로봇공학 ETF(BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKQ#BATS">ARKQ</a>)는 화요일에 엔비디아 주식 33,834주를 매각했다. 거래 규모는 430만 달러에 이른다. 이날 엔비디아 주가는 6.8% 오른 126.09달러로 마감했다.
이러한 움직임은 목요일 이후 <a href="https://www.benzinga.com/top-stories/24/06/39490865/nvidia-rebounds-over-6-after-550b-market-cap-loss">5500억 달러</a>의 감소를 보인 이 기술 대기업의 상당한 시가총액 손실에 따른 것이다. 그럼에도 불구하고 엔비디아는 화요일에 6% 이상 반등하여 마이크로소프트와 애플에 이어 세 번째로 가치 있는 기업으로서의 위치를 ​​되찾았다.
S&amp;P 500 지수에 대한 엔비디아의 영향력에 대한 우려가 제기되었으며, 일부 분석가들은 이 회사가 상당한 매도세를 겪을 경우 잠재적인 시장 침체가 더욱 확대될 수 있다고 <a href="https://www.benzinga.com/trading-ideas/technicals/24/06/39482710/nvidia-stock-drops-over-12-in-3-trading-days-indicators-suggest-whats-next">경고</a>했다. 이러한 우려에도 불구하고 엔비디아의 펀더멘털은 여전히 ​​강력하며, 데이터 센터와 자동차 부문의 강력한 성과에 힘입어 2024년 1분기 실적이 월스트리트의 기대치를 뛰어넘었다.
로쿠 거래
ARK 혁신 ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKK#NYSE">ARKK</a>)와 ARK 차세대 인터넷 ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKW#NYSE">ARKW</a>)는 화요일에 530만 달러 상당의 거래를 통해 로쿠의 주식 96,465주를 매입했다. 로쿠의 주가는 화요일 정규 세션에서 0.35% 상승한 54.64달러로 마감했다.
이러한 움직임은 최근 로쿠의 주가가 <a href="https://www.benzinga.com/general/entertainment/24/06/39422115/roku-stocks-wild-ride-bullish-analysts-bet-on-growth-despite-competitive-threats">강한 매수-매도 논쟁</a>에 휘말리면서 로쿠의 격동적인 시장 상황 속에서 이루어졌다. 경쟁적 위협에도 불구하고 낙관적인 투자자들은 여러 측면에서 로쿠의 수익 잠재력에 열광하고 있다.
로쿠의 라이벌인 넷플릭스는 최근 광고 인벤토리와 광고주 수요를 직접 연결하도록 설계된 <a href="https://www.benzinga.com/markets/equities/24/06/39295418/whats-going-on-with-tv-streaming-platform-rokus-shares-on-wednesday" target="_blank" rel="noopener">광고 기술 솔루션</a>인 로쿠 익스체인지(Roku Exchange)를 공개했다. 이 플랫폼은 스트리밍 우선 광고 기술의 상당한 발전을 나타내며 시장에서 로쿠의 입지를 더욱 공고히 한다.
기타 주요 거래:
<ul>
<li>아크 인베스트의 ARKG펀드가 깅코 바이오웍스 홀딩스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DNA#NASDAQ">DNA</a>)의 상당량의 주식을 매도했다. ARKG는 또한 아크투루스 테라퓨틱스 홀딩스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARCT#NASDAQ">ARCT</a>)와 10X 지노믹스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXG#NASDAQ">TXG</a>)의 주식을 매수했다.</li>
<li>ARKK 펀드는 줌 비디오 커뮤니케이션즈(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZM#NASDAQ">ZM</a>) 주식을 매도했으며, 페이저듀티(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PD#NYSE">PD</a>) 주식을 매수했다. ARKQ는 블레이드 에어 모빌리티(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLDE#NASDAQ">BLDE</a>)와 마크포지드 홀딩(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MKFG#NASDAQ">MKFG</a>)의 주식을 매수했다.</li>
</ul>
본 기사는 <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a>를 통해 작성되었으며, <a href="https://www.benzinga.com/author/shivdeep-dhaliwal" target="_blank" rel="noreferrer noopener">Shivdeep Dhaliwal</a>이 편집했습니다.

캐시 우드가 이끄는 아크 인베스트(Ark Invest)는 수요일에 로빈후드 마켓(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>) 및 줌 비디오 커뮤니케이션(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZM#NASDAQ">ZM</a>)괴 관련하여 상당한 거래를 했다.
로빈후드 주식의 거래
아크 인베스트는 Ark Fintech Innovation ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKF#NYSE">ARKF</a>)와 ARK Next Generation Internet ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKW#NYSE">ARKW</a>)를 통해 약 153만 달러 상당의 로빈후드 주식 64,706주를 매각했다. 이러한 움직임은 이 회사가 최근 시장 변동으로 인해 로빈후드의 <a href="https://www.benzinga.com/markets/equities/24/06/39263031/cathie-wood-lead-ark-invest-dumps-7-6m-worth-of-robinhood-shares-amid-gamestop-buzz-bitcoin-chop">보유 지분</a>을 줄인 후에 나온 것이다. 이 회사의 주가는 현재 5월 영업 데이터 발표 이후 상승하고 있다.
특히 로빈후드 거래는 비트코인(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>)과 이더리움(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>)의 가격이 약간의 상승세를 보였지만 연방준비은행(연준)의 금리 인하에 대한 매파적인 지침으로 인해 <a href="https://www.benzinga.com/markets/cryptocurrency/24/06/39303902/bitcoin-ethereum-dogecoin-fail-to-sustain-uptrend-after-feds-hawkish-guidance-analyst-fore" target="_blank" rel="noopener" data-google-interstitial="false">이 랠리는 지속되지 않았다</a>.
줌 주식 거래
아크 인베스트는 ARKW를 통해 54,165주, 약 330만달러 상당의 줌 주식을 매도했다. 이 결정은 회사가 지난달 <a href="https://www.benzinga.com/news/earnings/24/05/38926994/zoom-q1-earnings-revenue-beat-eps-beat-cash-flow-surges-continued-ai-integration-and-more">매출과 이익 예상치를 뛰어넘는 강력한 1분기 실적을 발표한 </a>이후의 결정이다.
다른 중요한 거래들:
<ul>
<li>아크 인베스트는 마크포지드 홀딩(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MKFG#NYSE">MKFG</a>)의 주식 21,260주를 ARK Autonomous Technology &amp; Robotics ETF(BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKQ#BATS">ARKQ</a>)를 통해 매수했다. 아크 인베스트는 ARK Space Exploration &amp; Innovation ETF(BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKX#BATS">ARKX</a>)를 통해 마크포지드 8,776주를 구매했다.</li>
<li>아크 인베스트는 페이저듀티(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PD#NYSE">PD</a>)의 주식 15,383주를 ARK Innovation ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKK#NYSE">ARKK</a>)를 통해 구매했다. 아크 인베스트는 ARK Genomic Revolution ETF(BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKG#BATS">ARKG</a>)를 통해 아크투러스 테라퓨틱스 홀딩스(NASDAQ:<a class="items-end ticker-link-wrapper inline-flex" href="https://www.benzinga.com/quote/arct" target="_blank" rel="dofollow noopener" aria-label="Go to Quote Page for ARCT">ARCT</a>)주식 39,589주를 매수했다.</li>
<li>아크 인베스트는 ARKW ETF를 통해 텔레닥 헬스 주식 229,654주를 매도했다. 아크 인베스트는 ARKK ETF를 통해 버브 테라퓨틱스 주식 125,257주를 매도했다. 이 회사는 ARKG ETF를 통해 버브 테라퓨틱스 주식 24,866주를 매도했다.</li>
</ul>
본 기사는 <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a>를 통해 제작되었으며, <a href="https://www.benzinga.com/author/shivdeep-dhaliwal" target="_blank" rel="noreferrer noopener">Shivdeep Dhaliwal</a>이 수정했습니다.

월요일에 캐시 우드가 주도하는 아크 인베스트(Ark Invest)는 로빈후드 마켓(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>)의 지분을 줄이는 중요한 조치를 취했다. 이 결정은 시장 변동 기간 중에 이루어졌으며 이 투자 회사가 자체 포트폴리오를 조정하는 최근 추세를 따랐다.
로빈후드(HOOD) 매매:
로빈후드에서 포지션을 축소하기로 한 아크 인베스트의 결정은 세 가지 ETF를 통해 실행되었다. ARK Fintech Innovation ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKF#NYSE">ARKF</a>)는 31,827주를 매각했고, ARK Innovation ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKK#NYSE">ARKK</a>)와 ARK Next Generation Internet ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKW#NYSE">ARKW</a>)는 각각 215,675주와 76,299주를 매각했다. 월요일 로빈후드의 종가 23.42달러를 기준으로 판매된 주식의 총 가치는 약 760만 달러이다.
로빈후드 주식의 변동성은 <a href="https://www.benzinga.com/news/24/06/39234943/whats-going-on-with-robinhood-stock" target="_blank" rel="noopener">밈 주식 열기가 부활</a>하는 가운데 발생했다. 최근 로빈후드의 CEO 블래디미어 테네브는 게임스탑에 투자한 것으로 유명한 로어링 키티(Roaring Kitty)이라고도 알려진 키스 길(Keith Gill)의 예정된 라이브 스트리밍으로 인한 트래픽 유입을 회사가 처리할 준비가 되었다고 발표했다. 이 회사는 또한 최근 <a href="https://www.benzinga.com/news/24/05/39047461/robinhood-markets-stock-jumps-on-1b-buyback-whats-going-on">10억 달러 규모의 자사주 매입</a>을 발표했는데, 이는 주가 상승 추세에 기여했다.
특히 비트코인(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>)과 이더리움(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>) 등 주요 코인들이 적자로 거래되면서 <a href="https://www.benzinga.com/markets/cryptocurrency/24/06/39262872/bitcoin-ethereum-dogecoin-remain-choppy-analyst-forecasts-2x-10x-increase-for-king-crypto-" target="_blank" rel="noopener">고르지 못한 암호화폐 시장</a>을 배경으로 거래가 성사됐다.
다른 중요한 거래:
<ul>
<li>이그젝트 사이언스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>): ARKG 및 ARKK를 통해 주식 매도.</li>
<li>아크투러스 테라퓨틱스 홀딩스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARCT#NASDAQ">ARCT</a>): ARKG를 통해 주식 매입.</li>
<li>텔라닥 헬스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>): ARKG를 통해 주식 매도.</li>
<li>인텔리아 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTLA#NASDAQ">NTLA</a>): ARKG 및 ARKK를 통해 주식 매입.</li>
<li>버브 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERV#NASDAQ">VERV</a>): ARKG 및 ARKK를 통해 주식 매도. 베라사이트(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCYT#NASDAQ">VCYT</a>): ARKG 및 ARKK를 통해 5,804주 매입.</li>
</ul>
다음 읽어보기: <a href="https://www.benzinga.com/markets/equities/24/06/39246807/investor-naval-ravikant-threatens-to-sell-all-tesla-holdings-if-ceo-musks-pay-plan-is-rejected-b?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">CEO 일자리 대안에 대한 투자자의 협상</a>
이 이야기는 <a href="https://www.benzinga.com/author/shivdeep-dhaliwal" target="_blank" rel="noreferrer noopener">Shivdeep Dhaliwal</a>의 편집을 거쳐 <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a>에 의해 제작되었습니다.

Comments

Arcturus Therapeutics

뉴스

에 대한 최신 뉴스 Arcturus Therapeutics (NASDAQ:ARCT) 주식

수요일, 6월 26, 2024

목요일, 6월 13, 2024

화요일, 6월 11, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌